TABLE 7.

THE ASSOCIATION OF TOP BIOMARKER GWAS SNPs WITH COPD-RELATED PHENOTYPES IN ECLIPSE^*

			FEV1		BMI		FFMI		% Emphysema		Exacerbation/2 Years
Biomarkers	SNP	Nearest Gene	Beta	P	Beta	P	Beta	P	Beta	P	Beta	P
CC16	rs17157266	AHNAK	−0.53	0.60	0.02	0.92	−0.06	0.58	−0.48	0.36	0.22	0.04
SP-D	rs8063863	ATP2C2	−0.79	0.24	−0.47	0.06	−0.30	0.02	−0.01	0.98	0.24	0.04
	rs8048576	ATP2C2	−0.68	0.35	−0.41	0.13	−0.32	0.02	−0.42	0.52	0.12	0.33
	rs7078012	SFTPD	0.09	0.89	0.73	0.005	0.33	0.01	−0.52	0.40	0.10	0.39
	rs1885553	SFTPD	0.30	0.55	0.39	0.04	0.11	0.26	−0.61	0.17	0.06	0.49
	rs1923539	RP11-479O17.4	−0.004	0.99	0.21	0.32	−0.02	0.83	−0.76	0.12	0.03	0.77

Definition of abbreviations: % Emphysema = % of low-attenuation area at −950 HU; BMI = body mass index; CC16 = Clara cell secretory protein; COPD = chronic obstructive pulmonary disease; ECLIPSE = Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints; Exacerbation/2 Years = reported frequency of COPD exacerbations during 2 years of follow-up; FFMI = fat-free mass index; GWAS = genome-wide association study; SNP = single nucleotide polymorphism; SP-D = surfactant protein D.

^*P values adjusted for age, sex, pack-years of smoking, current smoking status, and seven principal components for genetic ancestry.